Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep

David M. Mahvi*, Robert L. Conhaim, Bruce A. Harms, F. Kristian Storm

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Purpose of study: Interleukin-2 (IL-2) is a potent activator of lymphocytes, but its effectiveness as an anticancer agent is compromised by several adverse side effects including pulmonary edema. One explanation for the pulmonary toxicity of IL-2 is that activated lymphocytes directly induce the pulmonary vascular endothelium to become more leaky. Methods: To test this hypothesis the number of total lymphocytes, γδ T cells, and CD2- positive cells (αβ T cells and natural killer cells) in peripheral blood and lung lymph of sheep were compared before and after IL-2 infusion. Hemodynamic and lymph dynamic changes were also evaluated. Results: IL-2 decreased mean aortic pressure, increased cardiac output, lowered systemic vascular resistance, and doubled lung lymph flow (P ≤ 0.05), but had no effect on plasma or lymph oncotic pressure. The lymph protein concentration and the lymph-to-plasma protein concentration ratio were not different after IL-2 infusion. IL-2 had no effect on the number of total lymphocytes, γδ T cells, or CD2-positive cells in the peripheral blood. In contrast, the number of total lymphocytes, γδ T cells, and CD2-positive cells in lung lymph decreased significantly (P ≤ 0.05). Conclusions: The lymphocyte populations decreased more than could be explained by the increase in lymph flow, demonstrating that lung lymphocytes were not reduced simply by dilution. These results imply that the pulmonary edema associated with IL-2 is not caused by activated lymphocytes.

Original languageEnglish (US)
Pages (from-to)163-167
Number of pages5
JournalJournal of Surgical Research
Volume60
Issue number1
DOIs
StatePublished - Jan 1 1996

Fingerprint

Lymph
Interleukin-2
Sheep
Lymphocytes
Lung
Lymphocyte Count
T-Lymphocytes
Pulmonary Edema
Vascular Endothelium
Natural Killer Cells
Cardiac Output
Vascular Resistance
Antineoplastic Agents
Blood Proteins
Arterial Pressure
Hemodynamics
Pressure
Population

ASJC Scopus subject areas

  • Surgery

Cite this

Mahvi, David M. ; Conhaim, Robert L. ; Harms, Bruce A. ; Storm, F. Kristian. / Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep. In: Journal of Surgical Research. 1996 ; Vol. 60, No. 1. pp. 163-167.
@article{5b2e46e083a5468da36979d073ef75ae,
title = "Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep",
abstract = "Purpose of study: Interleukin-2 (IL-2) is a potent activator of lymphocytes, but its effectiveness as an anticancer agent is compromised by several adverse side effects including pulmonary edema. One explanation for the pulmonary toxicity of IL-2 is that activated lymphocytes directly induce the pulmonary vascular endothelium to become more leaky. Methods: To test this hypothesis the number of total lymphocytes, γδ T cells, and CD2- positive cells (αβ T cells and natural killer cells) in peripheral blood and lung lymph of sheep were compared before and after IL-2 infusion. Hemodynamic and lymph dynamic changes were also evaluated. Results: IL-2 decreased mean aortic pressure, increased cardiac output, lowered systemic vascular resistance, and doubled lung lymph flow (P ≤ 0.05), but had no effect on plasma or lymph oncotic pressure. The lymph protein concentration and the lymph-to-plasma protein concentration ratio were not different after IL-2 infusion. IL-2 had no effect on the number of total lymphocytes, γδ T cells, or CD2-positive cells in the peripheral blood. In contrast, the number of total lymphocytes, γδ T cells, and CD2-positive cells in lung lymph decreased significantly (P ≤ 0.05). Conclusions: The lymphocyte populations decreased more than could be explained by the increase in lymph flow, demonstrating that lung lymphocytes were not reduced simply by dilution. These results imply that the pulmonary edema associated with IL-2 is not caused by activated lymphocytes.",
author = "Mahvi, {David M.} and Conhaim, {Robert L.} and Harms, {Bruce A.} and Storm, {F. Kristian}",
year = "1996",
month = "1",
day = "1",
doi = "10.1006/jsre.1996.0026",
language = "English (US)",
volume = "60",
pages = "163--167",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep. / Mahvi, David M.; Conhaim, Robert L.; Harms, Bruce A.; Storm, F. Kristian.

In: Journal of Surgical Research, Vol. 60, No. 1, 01.01.1996, p. 163-167.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interleukin-2 does not sequester activated lymphocytes into lung lymph of sheep

AU - Mahvi, David M.

AU - Conhaim, Robert L.

AU - Harms, Bruce A.

AU - Storm, F. Kristian

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose of study: Interleukin-2 (IL-2) is a potent activator of lymphocytes, but its effectiveness as an anticancer agent is compromised by several adverse side effects including pulmonary edema. One explanation for the pulmonary toxicity of IL-2 is that activated lymphocytes directly induce the pulmonary vascular endothelium to become more leaky. Methods: To test this hypothesis the number of total lymphocytes, γδ T cells, and CD2- positive cells (αβ T cells and natural killer cells) in peripheral blood and lung lymph of sheep were compared before and after IL-2 infusion. Hemodynamic and lymph dynamic changes were also evaluated. Results: IL-2 decreased mean aortic pressure, increased cardiac output, lowered systemic vascular resistance, and doubled lung lymph flow (P ≤ 0.05), but had no effect on plasma or lymph oncotic pressure. The lymph protein concentration and the lymph-to-plasma protein concentration ratio were not different after IL-2 infusion. IL-2 had no effect on the number of total lymphocytes, γδ T cells, or CD2-positive cells in the peripheral blood. In contrast, the number of total lymphocytes, γδ T cells, and CD2-positive cells in lung lymph decreased significantly (P ≤ 0.05). Conclusions: The lymphocyte populations decreased more than could be explained by the increase in lymph flow, demonstrating that lung lymphocytes were not reduced simply by dilution. These results imply that the pulmonary edema associated with IL-2 is not caused by activated lymphocytes.

AB - Purpose of study: Interleukin-2 (IL-2) is a potent activator of lymphocytes, but its effectiveness as an anticancer agent is compromised by several adverse side effects including pulmonary edema. One explanation for the pulmonary toxicity of IL-2 is that activated lymphocytes directly induce the pulmonary vascular endothelium to become more leaky. Methods: To test this hypothesis the number of total lymphocytes, γδ T cells, and CD2- positive cells (αβ T cells and natural killer cells) in peripheral blood and lung lymph of sheep were compared before and after IL-2 infusion. Hemodynamic and lymph dynamic changes were also evaluated. Results: IL-2 decreased mean aortic pressure, increased cardiac output, lowered systemic vascular resistance, and doubled lung lymph flow (P ≤ 0.05), but had no effect on plasma or lymph oncotic pressure. The lymph protein concentration and the lymph-to-plasma protein concentration ratio were not different after IL-2 infusion. IL-2 had no effect on the number of total lymphocytes, γδ T cells, or CD2-positive cells in the peripheral blood. In contrast, the number of total lymphocytes, γδ T cells, and CD2-positive cells in lung lymph decreased significantly (P ≤ 0.05). Conclusions: The lymphocyte populations decreased more than could be explained by the increase in lymph flow, demonstrating that lung lymphocytes were not reduced simply by dilution. These results imply that the pulmonary edema associated with IL-2 is not caused by activated lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=0030027028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030027028&partnerID=8YFLogxK

U2 - 10.1006/jsre.1996.0026

DO - 10.1006/jsre.1996.0026

M3 - Article

C2 - 8592409

AN - SCOPUS:0030027028

VL - 60

SP - 163

EP - 167

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -